The United Kingdom and the United States have signed a landmark trade agreement that will ensure no levies on UK medicine shipments going into the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has pledged to increase spending on medicines through the National Health Service (NHS). This pledge secures that tariffs on these vital products will stay at nothing for a timeframe of 36 months.
This deal is in response to earlier warnings to significantly raise duties on patented drug imports, with potential rates mentioned reaching double the cost.
"This deal with the UK bolsters the global environment for new treatments and establishes much-needed equity to American-British medicine commerce," a release declared.
Economic Significance
Pharmaceuticals are one of the Britain's largest exports to the United States, which is easily the biggest destination for major British pharmaceutical firms.
Export figures reveal that in the 12 months to the end of the third quarter, the UK shipped medicines worth billions to the US. This amount represented 17.4% of all goods exports in that period.
"This guarantee secures work, boosts investment and facilitates the UK to become a international leader for life sciences," a minister commented.
Detailed UK Commitments
The deal includes several key changes from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a goal to raise total public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The sum manufacturers must refund to the NHS to prevent overspending will be capped at 15%. Previously, repayments exceeded twenty percent.
Recent Tensions
This agreement takes place against a ongoing tension between the drug companies and the British authorities over spending levels and regulatory access.
The disagreement were exacerbated by arguments that US customers were paying several times more for the equivalent treatments than consumers in the other developed nations.
Recently, several large drug company projects in the UK have been halted or abandoned, while major investments have been pledged toward American operations.
The Science Minister acknowledged that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had shrunk as a share of its resources over the last ten years.
